Free Newsletter
New compounds in works for tuberculosis
There's new evidence to support the theory that the enzyme protein kinase G offers a promising target in the fight against tuberculosis. The enzyme is secreted by the microbe that triggers TB and is believed to provide essential protection for the bug from the host's immune system, which tracks down and kills most pathogens. Scientists say they have a compound that can block the protein, but were worried about interfering with the action of other proteins also secreted by the microbe. Using X-ray crystallography, the researchers were able to pinpoint the exact method of inhibition and determined that it was unique to that one protein.
"Since we now know exactly what the requirements should be for a good blocker and how to avoid interference with host kinases, we should now be able to rationally design compounds that are highly effective against PknG," said lead author Jean Pieters, a professor of biochemistry at the University of Basle in Switzerland.
- read the report on the TB research from AFP
Related Article:
New compounds combat bacteria's defenses
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession





SHARE
WITH: